Identification of Novel Vaccine Candidates against Yellow Fever Virus from the Envelope Protein: An Insilico Approach

Year 2020, Volume: 10 Issue: 01, 31 - 46, 15.03.2020

Hind Abdelrahman Hassan Khoubieb Ali Abdelrahman Nasr Mohammed Nasr Yassir A. Almofti

https://doi.org/10.5799/jmid.700510

Abstract

Objectives: Yellow fever virus (YFV) is an enveloped positive sense RNA virus. It is the causative agent of the mosquito-borne disease yellow fever. The aim of this study was to design multi epitopes vaccine for YFV from envelope protein eliciting humoral and cellular immunity.
Methods: Twenty six YFV strains envelope proteins were retrieved from NCBI. The immune epitope database analysis resources (IEDB) were used for epitopes prediction.
Results: Eleven epitopes successfully passed all B cell prediction tools, among them four epitopes 33VMAPDKPSL41, 72DKCP77, 236PPHA239 and 385LTYQ388 demonstrated higher score in Emini and Kolaskar and tongaonker software. Thus were proposed as B cells epitopes. For T cells; 28 epitopes interacted with MHC-I and the best recognizable epitopes were 471MTMSMSMIL479, 363VLIEVNPPF371, 33VMAPDKPSL41 and 226REMHHLVEF234. For MHC-II ninety epitopes were predicted and the best epitopes were 284RVKLSALTL292, 363VLIEVNPPF371, 479LVGVIMMFL487 and 226REMHHLVEF234. Strikingly the epitope 33VMAPDKPSL41 successfully interacted with both B and T cells. Also 363VLIEVNPPF371 and 226REMHHLVEF234 demonstrated successful interaction with T cells. The population coverage was 84.66% and 99.91% for MHC-I and MHC-II epitopes, respectively, and 99.99% for all T cells epitopes.
Conclusions: Taken together nine epitopes successfully proposed as vaccine candidate against YFV. In vivo and in vitro clinical trials studies are required to elucidate the effectiveness of these epitopes as vaccine. J Microbiol Infect Dis 2020; 10(1):31-46.

Keywords

Yellow fever virus;, NCBI, IEDB, Immunoinformatics, Insilico vaccine

References

• 1. Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: The Viruses and Their Replication. In: Knipe, D.M. and Howley, O.M., Eds., Fields Virology, 5th Edition, Lippincot William & Wilkins, Philadelphia 2011; 1101-1151. 2. Tolle MA. Mosquito-borne diseases. Curr Probl Pediatr Adolesc Health Care 2009; 39(4):97-140. 3. Wilder-Smith A, W. Leong Y. Importation of yellow fever into China: assessing travel patterns. J Travel Med 2017; 24 (4). doi: 10.1093/jtm/tax008 4. Woodall JP and Yuill TM. Why is the yellow fever outbreak in Angola a 'threat to the entire world'?. Intern J Infect Dis 2016; 48:96-97. 5. Ellis BR and B. AD. The enigma of yellow fever in East Africa". Rev Med Virol 2008,18: p. 331-346. 6. Patricia Najera Hamrick, Sylvain Aldighieri, Gustavo Machado, et al. Geographic patterns and environmental factors associated with human yellow fever presence in the Americas. PLoS Negl Trop Dis 2017; 11(9): e0005897. 7. Mutebi JP, Barrett AD. The epidemiology of yellow fever in Africa. Microbes Infect 2002; 4 (14): 1459–1468. doi:10.1016/S1286-4579(02)00028-X. 8. Barrett AD, Higgs S. Yellow fever: a disease that has yet to be conquered. Annu Rev Entomol 2007; 52: 209–29. doi:10.1146/annurev.ento.52.110405.091454 9. Mutebi JP, Rijnbrand RC, Wang H, et al. Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the genus Flavivirus based on the 3' noncoding region". J Virol 2004; 78 (18): 9652–9665. doi:10.1128/JVI.78.18.9652-9665.2004. 10. Auguste AJ, Lemey P, Pybus OG, et al. Yellow fever virus maintenance in Trinidad and its dispersal throughout the Americas. J Virol 2010; 84 (19): 9967–9977. doi:10.1128/JVI.00588-10 11. de Souza RP, Foster PG, Sallum MA, et al. Detection of a new yellow fever virus lineage within the South American genotype I in BrazilJ". Med Virol 2010; 82 (1): 175–185. doi:10.1002/jmv.21606 12. Mir D, Delatorre E, Bonaldo M, Lourenço-de-Oliveira R, Vicente AC, Bello G. Phylodynamics of Yellow Fever Virus in the Americas: new insights into the origin of the 2017 Brazilian outbreak. Sci Rep 2017. 7 (1): 7385. doi:10.1038/s41598-017-07873-7 13. Vainio J, F Cutts, eds. Yellow Fever. WHO Division of Emerging and other Communicable Diseases Surveillance and Control 1998. 14. Monath TP. The absence of yellow fever in Asia: hypotheses. A cause for concern? Virus Inf Exch Newslett 1989; 106–107. 15. Cathey JT, Marr JS. Yellow fever, Asia and the East African slave trade. Trans R Soc Trop Med Hyg 2014; 108(5): 252–257. doi:10.1093/trstmh/tru043 16. Reinhardt B, Jaspert R, Niedrig M, Kostner C, L'age-Stehr J. Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 1998; 56:159-167. 17. Jennings AD, Gibson CA, Miller BR, et al. Analysis of a yellow fever virus isolated from a fatal case of vaccine-associated human encephalitis. J Infect 1994; 169: p. 512-518. 18. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, Rawlinson WD. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 2001; 358: p. 121-122. 19. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, et al; Brazilian Yellow Fever Vaccine Evaluation Group. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001; 358: p. 91-97. 20. Yang H, Yang H, Li Z, et al. Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice. Vaccine 2018; 36(18): p. 2450-2455 21. Bassi MR, Larsen MA, Kongsgaard M, et al. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice. PLOS.org 2016; 10(2):e0004464. doi: 10.1371/journal.pntd.0004464 22. Ying-Tsang Lo, Tun-Wen Pai, Wei-Kuo Wu, Hao-Teng C. Prediction of conformational epitopes with the use of a knowledge-based energy function and geometrically related neighboring residue characteristics. BMC Bioinformatics 2013; 14: S3. 23. Pappalardo F, Pennisi M, Castiglione F, Motta S. Vaccine protocols optimization: in silico experiences, Biotech Adv 2010; 28: 82-93. 24. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999; 41: p. 95-98. 25. Peters B and S. A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 2005; 6: p. 132. 26. Zhang Q, Wang P, Kim Y, et al. Immune epitope database analysis resource (IEDB-AR). Nucleic Acids Res 2008; 36: W513–W518. 27. Maciel M Jr, Kellathur SN, Chikhlikar P, et al. Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice model. Virology 2008; 378: 105–117. 28. Tottey S, Shoji Y, Jones RM, et al. Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models. Ameri Soci Trop Med Hyg 2018; 98(2): 420-431. 29. de Melo AB, Nascimento EJ, Braga-Neto U, et al. T-cell Memory Responses Elicited by Yellow Fever Vaccine are Targeted to Overlapping Epitopes Containing Multiple HLA-I and-II Binding Motifs. 2013; PloS NegI Trop Dis 7(1):e1938. https://doi.org/10.1371/journal.pntd.0001938. 30. Maciel M Jr, Cruz Fda S, Cordeiro MT, et al. A DNA Vaccine against Yellow Fever Virus: Development and Evaluation. plos.org 2015; 13;9(4):e0003693. doi: 10.1371/journal.pntd.0003693. eCollection.